Analyst Price Target is $8.75
▲ +1,930.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $8.75, with a high forecast of $16.00 and a low forecast of $1.50. The average price target represents a 1,930.16% upside from the last price of $0.43.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Palisade Bio. This Buy consensus rating has held steady for over two years.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.